review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | J Robert Kane | Q86215181 |
Maciej S Lesniak | Q89840113 | ||
Deepak Kanojia | Q42560627 | ||
P2093 | author name string | Jason Miska | |
Jacob S Young | |||
Julius W Kim | |||
P2860 | cites work | Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth | Q48752349 |
Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. | Q55475653 | ||
Thunder and lightning: immunotherapy and oncolytic viruses collide | Q24597894 | ||
Anti-angiogenic gene therapy in the treatment of malignant gliomas | Q26866276 | ||
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates | Q27007519 | ||
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities | Q27011598 | ||
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics | Q28141424 | ||
Functionalized carbon nanotubes for potential medicinal applications | Q28392143 | ||
Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells | Q28742284 | ||
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering | Q29547524 | ||
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering | Q29615505 | ||
Pluripotency of mesenchymal stem cells derived from adult marrow | Q29617959 | ||
Cancer immunotherapy comes of age | Q29619918 | ||
Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles | Q30479575 | ||
MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism | Q30502129 | ||
Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma | Q30577878 | ||
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. | Q33410831 | ||
Near infrared light-triggered drug generation and release from gold nanoparticle carriers for photodynamic therapy | Q33578775 | ||
Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope | Q45887671 | ||
Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier | Q46591212 | ||
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines | Q48154511 | ||
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function | Q48220006 | ||
Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody | Q33629775 | ||
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. | Q33638847 | ||
Hypoxia potentiates glioma-mediated immunosuppression | Q33809268 | ||
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. | Q33819663 | ||
Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. | Q34159409 | ||
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma | Q34208293 | ||
Gene therapy for human genetic disease? | Q34227501 | ||
FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors. | Q34243615 | ||
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. | Q34276759 | ||
Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma | Q34480527 | ||
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? | Q34480557 | ||
An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer | Q34577155 | ||
A computational model for predicting nanoparticle accumulation in tumor vasculature | Q34611599 | ||
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy | Q34764143 | ||
Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives | Q35085457 | ||
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy | Q35119552 | ||
Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation | Q35119851 | ||
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts | Q35175677 | ||
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector | Q35696378 | ||
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas | Q35827956 | ||
Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles | Q36659125 | ||
Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma | Q36811505 | ||
Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma | Q36861449 | ||
Targeted pharmaceutical nanocarriers for cancer therapy and imaging | Q36871933 | ||
Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. | Q36879211 | ||
The state of the art of adeno-associated virus-based vectors in gene therapy | Q36972714 | ||
Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo | Q37096766 | ||
Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas | Q37109246 | ||
Adenoviral virotherapy for malignant brain tumors | Q37223846 | ||
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide | Q37356520 | ||
DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. | Q37395354 | ||
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies | Q37396577 | ||
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection | Q37397827 | ||
Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy | Q37427886 | ||
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors | Q37447217 | ||
Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas | Q37461117 | ||
Glioma virus therapies between bench and bedside | Q37580510 | ||
Neuro-oncology: The long and winding road--gene therapy for glioma | Q37591425 | ||
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas | Q37658308 | ||
Eradication of brain tumor stem cells with an oncolytic adenovirus | Q37776552 | ||
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors | Q37804933 | ||
The effect of nanoparticle size, shape, and surface chemistry on biological systems | Q38004588 | ||
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. | Q38110540 | ||
Stimuli-responsive nanocarriers for drug delivery. | Q38154805 | ||
Involvement of tumor acidification in brain cancer pathophysiology | Q38160479 | ||
Therapeutic cell carriers: a potential road to cure glioma | Q38213836 | ||
A new X-ray activated nanoparticle photosensitizer for cancer treatment. | Q38976020 | ||
Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. | Q39008799 | ||
Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells | Q39166193 | ||
Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma | Q39360531 | ||
A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas | Q39390470 | ||
Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. | Q39672199 | ||
Integration of adenovirus thymidine kinase suicide-gene therapy with surgery and radiation therapy for malignant glioma | Q39678222 | ||
Uptake and intracellular release kinetics of liposome formulations in glioma cells | Q39689005 | ||
HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells | Q39797615 | ||
Powerful inner/outer controlled multi-target magnetic nanoparticle drug carrier prepared by liquid photo-immobilization | Q39818289 | ||
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. | Q40481710 | ||
Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. | Q40551463 | ||
Efficacy of adenoviral p53 delivery with SCH58500 in the intracranial 9L and RG2 models | Q40654723 | ||
Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth | Q41114486 | ||
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial | Q42284125 | ||
The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. | Q43061941 | ||
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy | Q43464631 | ||
Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells | Q43767316 | ||
Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes | Q43830296 | ||
Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector | Q43890874 | ||
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses | Q43941683 | ||
Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario | Q44763875 | ||
Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12 | Q45710750 | ||
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. | Q45739549 | ||
An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma | Q45858863 | ||
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results | Q45863348 | ||
Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats | Q45868078 | ||
Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. | Q45883468 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | gene therapy | Q213901 |
glioblastoma | Q282142 | ||
P304 | page(s) | ii24-ii36 | |
P577 | publication date | 2015-03-01 | |
P1433 | published in | Neuro-Oncology | Q15724471 |
P1476 | title | Sui generis: gene therapy and delivery systems for the treatment of glioblastoma | |
P478 | volume | 17 Suppl 2 |
Q38675900 | A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. |
Q47549547 | A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma |
Q36367252 | A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors |
Q36155208 | Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma |
Q38801098 | Future directions of operative neuro-oncology. |
Q90618650 | Glioblastoma Treatment Modalities besides Surgery |
Q52366335 | Glioblastoma: new therapeutic strategies to address cellular and genomic complexity. |
Q64963902 | Harnessing Microglia and Macrophages for the Treatment of Glioblastoma. |
Q47141309 | Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma |
Q38989773 | Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy |
Q45864012 | Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy |
Q64066303 | Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy |
Q26783167 | Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme |
Q92344294 | Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models |
Q26776345 | Overview of current immunotherapeutic strategies for glioma |
Q38833819 | PK11195-chitosan-graft-polyethylenimine-modified SPION as a mitochondria-targeting gene carrier. |
Q64266370 | Polyplexes of Functional PAMAM Dendrimer/Apoptin Gene Induce Apoptosis of Human Primary Glioma Cells In Vitro |
Q37239071 | Recent advances and future of immunotherapy for glioblastoma |
Q36904198 | Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters |
Q37109638 | The homing and inhibiting effects of hNSCs-BMP4 on human glioma stem cells |
Q91968731 | Viral vector: potential therapeutic for glioblastoma multiforme |
Search more.